You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2024

Details for Patent: RE43879

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent RE43879 protect, and when does it expire?

Patent RE43879 protects FETZIMA and is included in one NDA.

This patent has forty-six patent family members in twenty-seven countries.

Summary for Patent: RE43879

Scope and claims summary:

Title:	Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug
Abstract:	The present invention concerns the use of a mixture of enantiomers enriched in the dextrogyral enantiomer of milnacipran and/or of at least one of its metabolites, as well as their pharmaceutically-acceptable salts, for the preparation of a drug intended to prevent or to treat disorders that can be managed by double inhibition of serotonin (5-HT) and norepinephrine (NE) reuptake, while limiting the risks of cardiovascular disturbances and/or organ and/or tissue toxicity.
Inventor(s):	Deregnaucourt; Jean (Paris, FR), Grosse; Richard (Gidy, FR)
Assignee:	Pierre Fabre Medicament (Paris, FR)
Application Number:	13/406,415
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent RE43879
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent RE43879

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie	FETZIMA	levomilnacipran hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	204168-001	Jul 25, 2013		RX	Yes	No	⤷ Subscribe	⤷ Subscribe				TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)	⤷ Subscribe
Abbvie	FETZIMA	levomilnacipran hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	204168-002	Jul 25, 2013		RX	Yes	No	⤷ Subscribe	⤷ Subscribe				TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)	⤷ Subscribe
Abbvie	FETZIMA	levomilnacipran hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	204168-003	Jul 25, 2013		RX	Yes	No	⤷ Subscribe	⤷ Subscribe				TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)	⤷ Subscribe
Abbvie	FETZIMA	levomilnacipran hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	204168-004	Jul 25, 2013		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe				TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: RE43879

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
France	03 01849	Feb 14, 2003

International Family Members for US Patent RE43879

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	401872	⤷ Subscribe
Austria	501716	⤷ Subscribe
Australia	2004216452	⤷ Subscribe
Brazil	PI0407256	⤷ Subscribe
Canada	2514948	⤷ Subscribe
China	1750817	⤷ Subscribe
Cyprus	1108287	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.